glp-1 and cancer risk GLP-1s tied to lower for 10 types of compared with insulin in type 2 diabetes Forest plot of GLP-1 receptor

Transitioning from weight loss to maintenance Determining goal weight achievement: Lost 10-12% body weight (cagrilintide alone) Lost 15-25% body weight (CagriSema) Weight stable for 4-8 weeks Satisfied with current weight Ready to focus on maintenance Maintenance dose options comparison: Option 1: Continue same dose Keep cagrilintide at 2.4mg weekly Ensures no regain Most conservative approach Highest cost Option 2: Reduce dose slightly Decrease to 1.8-2.0mg weekly Monitor weight for 4 weeks If stable, maintain If gaining, increase back 20-25% cost savings Option 3: Try every 10 days Instead of weekly, inject every 10 days Effectively 30% dose reduction Some maintain weight this way Requires close monitoring Recommendation: Try Option 2 first (reduce to 1.8-2.0mg)

When combined with semaglutide (a GLP-1 agonist), the combination targets two separate appetite pathways simultaneously, producing greater weight loss than either drug alone

RCR (Respiratory Control Ratio): Ratio of V3 to V4, a measure of coupling efficiency

It supports normal brain function

Always consult a doctor before starting any medicine

Atherosclerosis Up to 85% of cardiovascular deaths are related to atherosclerotic heart disease, which occurs as heart attacks and strokes